{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:28:01Z","timestamp":1769704081457,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The therapeutic standard for post-autologous stem cell transplantation (ASCT) maintenance in multiple myeloma (MM) is evolving, with daratumumab-based regimens emerging as highly effective. However, access to such therapies remains limited in regions like China. This study evaluated the real-world efficacy and safety of the oral proteasome inhibitor ixazomib as a practical alternative for maintenance therapy in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective analysis included 28 MM patients who received ixazomib-based maintenance (monotherapy or combination) for \u22655 months after ASCT (from a total cohort of 64 ASCT recipients) between August 2019 and August 2023. Treatment was assigned based on mSMART 3.0 risk stratification and adjusted per clinical circumstances. The primary endpoint was progression-free survival (PFS). Secondary endpoints included treatment response, minimal residual disease (MRD) status, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the patients was 57 years (range: 48\u201369). Before ASCT, 9 patients (32.1%) achieved complete response (CR), 7 (25.0%) achieved very good partial response (VGPR), and 12 (42.9%) achieved partial response (PR). After ASCT, responses deepened: 17 patients (60.7%) achieved CR, 6 (21.4%) VGPR, and 5 (17.9%) PR. Following Ixazomib maintenance, 15 patients (53.5%) were in CR, 8 (28.6%) in VGPR, and 5 (17.9%) in PR. Four patients experienced disease progression during follow-up. The incidence of grade \u2265 3 adverse events was 3.6%. The estimated 3-year PFS and overall survival rates were 70.8% (95% CI, 52.18%\u201389.42%) and 87.4% (95% CI, 73.88%\u2013100.92%), respectively. Notably, patients who sustained MRD negativity for over 1 year had an estimated 3-year PFS of 100%, significantly higher than that of MRD-positive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Within the constraints of the current Chinese clinical context, ixazomib-based maintenance therapy demonstrates favorable efficacy and a manageable safety profile for MM patients after ASCT, offering a viable and accessible alternative. Achieving sustained MRD negativity is critically important for long-term outcomes, reinforcing its value as a key treatment goal. These real-world findings support the role of ixazomib, particularly for patients ineligible for or intolerant to standard regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1680704","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:30Z","timestamp":1769664150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Ixazomib-based maintenance therapy after autologous hematopoietic stem cell transplantation in multiple myeloma patients: a retrospective analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengyuan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaile","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jha2.739","article-title":"Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States","volume":"4","author":"Richter","year":"2023","journal-title":"EJHaem"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","article-title":"The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050","volume":"611","author":"Dou","year":"2025","journal-title":"Cancer Lett"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish myeloma registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","article-title":"Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation","volume":"102","author":"Martino","year":"2023","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41408-025-01387-6","article-title":"35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myelome (IFM) experience","volume":"15","author":"Moreau","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/ajh.27451","article-title":"Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: a study of the worldwide network for blood and marrow transplantation (WBMT)","volume":"99","author":"Garderet","year":"2024","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/ajh.27029","article-title":"Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: the MD Anderson experience","volume":"98","author":"Pasvolsky","year":"2023","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"752.e1","DOI":"10.1016\/j.jtct.2022.07.028","article-title":"Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma","volume":"28","author":"Pasvolsky","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1038\/s41375-022-01691-1","article-title":"Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma","volume":"36","author":"Slade","year":"2022","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First Global Approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2021.280394","article-title":"All-oral triplet combination of Ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study","volume":"107","author":"Touzeau","year":"2022","journal-title":"Haematologica"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288320","article-title":"Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers","author":"May","year":"2025","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/cancers16051024","article-title":"Ixazomib, lenalidomide, and dexamethasone (IRD) treatment with cytogenetic risk-based maintenance in transplant-eligible myeloma: a phase 2 multicenter study by the Nordic myeloma study group","volume":"16","author":"Partanen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"166.e1","DOI":"10.1016\/j.jtct.2024.12.023","article-title":"Outcomes of standard-risk multiple myeloma patients who undergo upfront autologous hematopoietic stem cell transplantation","volume":"31","author":"Pasvolsky","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3324\/haematol.2020.259093","article-title":"The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian myeloma research group national database","volume":"106","author":"Cherniawsky","year":"2021","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1007\/s00277-024-05995-3","article-title":"Correction to: comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021","volume":"103","author":"Kysenius","year":"2024","journal-title":"Ann Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1016\/j.clml.2020.06.024","article-title":"Feasibility of long-term proteasome inhibition in multiple myeloma by in-class transition from bortezomib to ixazomib","volume":"20","author":"Manda","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(24)00249-7","article-title":"Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"11","author":"Cook","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1680704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:30Z","timestamp":1769664150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1680704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1680704"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1680704","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1680704"}}